Helix Biopharma Corp.
HBPCF
$1.73
$1.13188.97%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.76% | 82.06% | 19.45% | -44.83% | -5.97% |
| Total Depreciation and Amortization | -51.72% | -68.18% | -27.59% | -36.36% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.44% | -98.67% | 296.12% | 149.19% | -1,022.22% |
| Change in Net Operating Assets | -144.60% | -76.27% | -85.82% | 144.48% | 207.60% |
| Cash from Operations | -39.64% | 13.53% | -17.19% | 40.22% | 53.76% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -- | -- | 167.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -94.20% | 269,800.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.09% | -94.46% | 271,214.29% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 149.94% | -274.64% | -307.29% | 210.43% | -201.84% |